TrialNerd_Beth said:

Short answer: the data supports it for most people

I respect TrialNerd_Beth perspective but I think this oversimplifies things a bit. Re: Has anyone dealt with cheapest — the effect size varies considerably by population.

I am not saying TrialNerd_Beth wrong entirely — just that the picture is more nuanced than a blanket statement. The SUSTAIN data specifically shows different outcomes in different metabolic phenotypes.

Relevant to Has anyone dealt with cheapest — here is my latest bloodwork comparison:

Key improvements: A1C 7.2% → 5.3%, triglycerides 199 → 99 mg/dL, hsCRP 6.0 → 1.1 mg/L. All on tirzepatide for 15 months.

The inflammatory marker drop is what impresses me most. Consistent with the SELECT trial's cardiovascular findings.

Thank you hyun_seoul! This is incredibly helpful. Bookmarking for later. 🙏

Slightly tangential to Has anyone dealt with but chris_chi24 reminded me — has the insurance landscape changed recently?

I know it is not exactly on-topic but it seems related enough to ask here rather than starting a new thread. Apologies if this has been covered — I did search first.

Moderator note: Reminder: nothing posted here constitutes medical advice. Consult your healthcare provider.

Tagging this for the weekly digest. 👍